Cancer Predisposition Syndromes in Neuro-Oncology.


Journal

Seminars in neurology
ISSN: 1098-9021
Titre abrégé: Semin Neurol
Pays: United States
ID NLM: 8111343

Informations de publication

Date de publication:
14 Dec 2023
Historique:
medline: 15 12 2023
pubmed: 15 12 2023
entrez: 14 12 2023
Statut: aheadofprint

Résumé

Although most primary central and peripheral nervous system (NS) tumors occur sporadically, there are a subset that may arise in the context of a cancer predisposition syndrome. These syndromes occur due to a pathogenic mutation in a gene that normally functions as a tumor suppressor. With increased understanding of the molecular pathogenesis of these tumors, more people have been identified with a cancer predisposition syndrome. Identification is crucial, as this informs surveillance, diagnosis, and treatment options. Moreover, relatives can also be identified through genetic testing. Although there are many cancer predisposition syndromes that increase the risk of NS tumors, in this review, we focus on three of the most common cancer predisposition syndromes, neurofibromatosis type 1, neurofibromatosis type 2, and tuberous sclerosis complex type 1 and type 2, emphasizing the clinical manifestations, surveillance guidelines, and treatment options.

Identifiants

pubmed: 38096910
doi: 10.1055/s-0043-1777702
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

None declared.

Auteurs

Brian Na (B)

Department of Neurology, UCLA David Geffen School of Medicine, Los Angeles, California.

Shilp Shah (S)

Department of Bioengineering, UCLA Samueli School of Engineering, Los Angeles, California.

Phioanh Leia Nghiemphu (PL)

Department of Neurology, UCLA David Geffen School of Medicine, Los Angeles, California.

Classifications MeSH